SCHEMBL633367

SCHEMBL633367

CC(Br)C(=O)c1cccc(Br)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA1 P02708 1/20 0.58
CHRNG P07510 1/20 0.58
CHRNB1 P11230 1/20 0.58
CHRNB2 P17787 1/20 0.58
SLC6A2 P23975 1/20 0.58
CHRNB4 P30926 1/20 0.58
CHRNA3 P32297 1/20 0.58
CHRNA4 P43681 1/20 0.58
SLC6A3 Q01959 1/20 0.58
CHRND Q07001 1/20 0.58
PARP1 P09874 1/20 0.55
ALDH1A1 P00352 4/20 0.51
CYP1A2 P05177 3/20 0.51
CYP2C9 P11712 2/20 0.51
SMN1; SMN2 Q16637 6/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30310283 1.00 CHRNA1 (0.58) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL29922182 0.86 CHRNA1 (0.59) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL3125040 0.86 CHRNA1 (0.59) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL2599175 0.85 CHRNA1 (0.58) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL15007152 0.85 CHRNA1 (0.58) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL4665718 0.83 CHRNA1 (0.56) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL9040971 0.83 PARP1 (0.58) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL28567525 0.81 CHRNA1 (0.55) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
Hydrochloric Acid SCHEMBL22557048 0.81 PARP1 (0.56) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL634070 0.81 SLC6A2 (0.55) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250033082-A1 METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS ADAMA MAKHTESHIM LTD. (IL) 2025-01-30 US claimed
EP-4423178-A1 METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS ADAMA MAKHTESHIM LTD. (IL) 2024-09-04 EP claimed
CN-118201991-A Methods and compositions for reducing solvent release from agrochemical formulations and reducing agrochemical formulation odor 安道麦马克西姆有限公司 2024-06-14 CN claimed
WO-2023073536-A1 METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS ADAMA MAKHTESHIM LTD. (IL) 2023-05-04 WO claimed
US-20250033082-A1 METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS ADAMA MAKHTESHIM LTD. (IL) 2025-01-30 US disclosed
CN-118201991-A Methods and compositions for reducing solvent release from agrochemical formulations and reducing agrochemical formulation odor 安道麦马克西姆有限公司 2024-06-14 CN disclosed
WO-2023073536-A1 METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS ADAMA MAKHTESHIM LTD. (IL) 2023-05-04 WO disclosed
US-10919841-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2021-02-16 US disclosed
WO-2020212350-A1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-10-22 WO disclosed
US-20180215701-A1 MONOAMINE REUPTAKE INHIBITORS RES TRIANGLE INST (US) 2018-08-02 US disclosed
WO-2017214505-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2017-12-14 WO disclosed
US-9562001-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2017-02-07 US disclosed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 WO disclosed
EP-1370539-A1 HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES K.U. Leuven Research and Development (BE) 2003-12-17 EP disclosed
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 US disclosed
WO-2003060078-A2 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO disclosed
WO-2002068395-A1 HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2002-09-06 WO disclosed
US-6172102-B1 POLLAKIURIA OR URINARY INCONTINENCE NIPPON SHINYAKU CO., LTD. (JP) 2001-01-09 US disclosed
US-5998459-A INCOTINENCE THERAPY NIPPON SHINYAKU CO., LTD. (JP) 1999-12-07 US disclosed
EP-0842923-A1 PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION NIPPON SHINYAKU COMPANY, LIMITED (JP) 1998-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919841-B2 Monoamine reuptake inhibitors SLC6A2, SLC6A4, SLC6A3 CHRNA1 186/4885CHRNG 477/4885CHRNB1 168/4885
US-20180215701-A1 MONOAMINE REUPTAKE INHIBITORS SLC6A2, SLC6A4, SLC6A3 CHRNA1 186/4885CHRNG 477/4885CHRNB1 168/4885
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 CHRNA1 735/4885CHRNG 392/4885CHRNB1 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.